What is RISA?
Founded in 2024, RISA Labs operates at the intersection of artificial intelligence and oncology care management. The company specializes in automating the notoriously complex prior authorization process, a critical pain point that often leads to treatment delays and administrative burden for healthcare providers. By integrating directly with major Electronic Health Record (EHR) systems, RISA utilizes a sophisticated rules engine and generative AI to streamline compliance and operational workflows. This technological approach not only reduces the time-to-treatment for patients but also enhances the overall efficiency of oncology departments, effectively bridging the gap between clinical necessity and administrative approval.
How much funding has RISA raised?
RISA has raised a total of $14.6M across 2 funding rounds:
Angel/Seed
$3.5M
Series A
$11.1M
Angel/Seed (2025): $3.5M with participation from Binny Bansal, General Catalyst, and Oncology Ventures
Series A (2026): $11.1M led by Optum Ventures
Key Investors in RISA
General Catalyst
General Catalyst is a prominent venture capital firm that partners with founders to build enduring enterprises, leveraging deep sector expertise in healthcare and enterprise software to accelerate growth.
Oncology Ventures
Oncology Ventures focuses exclusively on healthcare data companies that address critical challenges in cancer care, aiming to improve patient outcomes through AI-powered treatment optimization.
Optum Ventures
Optum Ventures invests in early-stage companies poised to disrupt the healthcare status quo, providing strategic support to improve the overall quality and efficiency of the health system.
What's next for RISA?
With the successful closure of its Series A round, RISA is well-positioned to accelerate its market penetration and expand its integration capabilities across a broader range of EHR platforms. The company's roadmap likely includes scaling its engineering team to refine its multi-agent AI models and deepening its partnerships with major healthcare providers to ensure widespread adoption. As the regulatory environment for AI in healthcare continues to evolve, RISA's focus on compliance and evidence-based automation will be a key differentiator. The firm is expected to leverage its recent backing to solidify its position as a leader in oncology-focused administrative technology, potentially exploring new therapeutic areas where similar authorization complexities exist.
See full RISA company page
